Acuta Capital Partners’s Assembly Biosciences ASMB Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2019
Q4
Sell
-10,958
Closed -$1.29M 41
2019
Q3
$1.29M Sell
10,958
-2,209
-17% -$334K 0.93% 24
2019
Q2
$2.13M Sell
13,167
-50,208
-79% -$9.54M 0.76% 27
2019
Q1
$15M Buy
63,375
+3,500
+6% +$886K 7.12% 3
2018
Q4
$16.3M Sell
59,875
-17,625
-23% -$5.1M 12.4% 2
2018
Q3
$34.5M Sell
77,500
-19,333
-20% -$9.06M 12.32% 2
2018
Q2
$45.6M Buy
96,833
+3,916
+4% +$2.07M 8.11% 3
2018
Q1
$54.8M Buy
92,917
+2,325
+3% +$1.44M 8.95% 3
2017
Q4
$49.2M Buy
90,592
+7,259
+9% +$3.29M 9.29% 2
2017
Q3
$34.9M Sell
83,333
-2,506
-3% -$768K 6.26% 4
2017
Q2
$21.3M Sell
85,839
-5,828
-6% -$1.64M 5.95% 6
2017
Q1
$28M Buy
91,667
+10,284
+13% +$2.52M 6.65% 4
2016
Q4
$11.9M Buy
81,383
+55,199
+211% +$8.21M 4.41% 7
2016
Q3
$2.27M Buy
26,184
+7,397
+39% +$571K 0.85% 33
2016
Q2
$1.25M Buy
+18,787
New +$1.23M 0.6% 42
2015
Q1
Sell
-317
Closed -$30K 53
2014
Q4
$30K Buy
+317
New +$31.2K 0.02% 64

Other funds holding ASMB

Acuta Capital Partners's ASMB Position: Q4 2019 in Review

Acuta Capital Partners sold out of Assembly Biosciences (ASMB) in Q4 2019, closing a stake of 10,958 shares — an estimated $1.29M sold.

Acuta Capital Partners first reported a position in ASMB in Q4 2014 and held it in 15 quarters. The position peaked at $54.8M in Q1 2018. 100 funds tracked by Wall St. Rank hold ASMB as of Q4 2019.

  • Acuta Capital Partners reported no remaining Assembly Biosciences position as of Q4 2019 after selling out during the quarter.
  • Acuta Capital Partners sold 10,958 Assembly Biosciences shares in Q4 2019, an estimated $1.29M.
  • Acuta Capital Partners first reported a position in Assembly Biosciences in Q4 2014 and held it in 15 quarters.
  • Acuta Capital Partners's Assembly Biosciences position peaked at $54.8M in Q1 2018.
  • 100 funds tracked by Wall St. Rank held Assembly Biosciences as of Q4 2019.

Based on Acuta Capital Partners's 13F filing for Q4 2019, filed 14 Feb 2020.